BAL up 1,140% from IPO Price: Research Update

BAL up 1,140% from IPO Price: Research Update

Bellamy’s Organic (BAL) is Australia’s leading producer of Australian-made organic baby food products.

BAL was one of Australia’s top-performing shares in 2015. BAL debuted on the ASX with an IPO price of $1.00 per share in 2014. It has since risen 1,140 per cent to circa $12.40 per share.

BAL’s growth has been buoyed through surging demand for Australian-made organic infant formula, largely from China.

BAL suggest that, due to global demand over recent years, the cost of organic milk is now three times the cost of conventional milk.

Morgans recently provided a number of research updates explaining recent company developments.

Morgans highlight that BAL has implemented large price rises (+20%) across its infant formula range in Australia. Only one month of price rises were included in BAL’s recent 1H16 result.

Alongside 1H16 sales of $105.1m, NPAT grew 286% to $13.7m. This was in line with Morgans most recent forecast. The broker attributes: strong publicity and brand name; increased sales; distribution efficiencies; and online channels.

Moving forward, Morgans suggest the contribution of recent price rises will be amplified. The broker believes 2H16 will permit BAL to increase production and also anticipates strategic investments in growth opportunities.

Morgans suggest additional tailwinds supporting double-digit growth include: new products and packaging; a strong balance sheet; improvements in cash flow and working capital; beneficial consumer and industry dynamics.

Noting potential risks, Morgans remain mindful of competition, raw material supply, brand damage, e-commerce regulations, and proposed legislation which would require Chinese labels on formula before distribution to China.

On this last point, BAL commented they are well placed to benefit from packaging changes through greater control over their online trading.

For FY16, the broker recently forecast $246.8M in revenue and upgraded NPAT forecasts by 35% to $33.1m.

Morgans retain an “Add” recommendation and raise their target price 19.8% to $16.65. This represents circa 34% upside to Wednesday’s closing price.

Join IPO Society to receive invitations to participate in upcoming IPO opportunities, research and news.

The team at

IPO Society

The information contained on this website in no way reflects the opinions of IPO Society. It is provided for informational services only. It does not constitute an offer to sell or a solicitation to buy any security or other financial instrument. The information is general in nature and does not take into account your personal situation. You should consider whether the information is appropriate to your needs, and where appropriate, seek professional advice from a financial adviser. Detailed information may be needed to make an investment decision, for example: financial statements; a business plan; information about ownership of intellectual or industrial property; or expert opinions including valuations or auditors’ reports. The information contained on this website is not intended to be the only information on which an investment decision is made and is not a substitute for a disclosure document, product disclosure statement or any other notice that may be required under the Act, as the Act may apply to the investment.

Follow us for the latest IPO news
BAL up 1,140% from IPO Price: Research Update
Tagged on: